Left Atrial Appendage Occlusion Guided by 3D Printing

NCT03330210 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2020-03-10

No results posted yet for this study

Summary

Left atrial appendage closure (LAAC) was approved by the ESC guidelines as a stroke prevention alternative to warfarin for patients with nonvalvular atrial fibrillation in patients at high risk of bleeding (IIbB).

Although the overall LAAC benefice, in term of prevention of stroke or embolisme and decresing the anticoagulant-related risk of bleeding is already demonstrated, however the procedure success and safety, critically depends on understanding LAA anatomy and adequate pre-procedure planning.

3D-printed patient-specific adaptive and flexible LA models have demonstrated in a previous study an improving in LAAO device sizing, a better pre-procedural planning of the optimal trans-septal puncture site, by incorporating all anatomical variations and an improuving patient outcomes by reducing procedure time and number of prostheses employed per patient.

This technique is now used in several surgical centers in France and large prospective evaluation of the practice is necessary.

Conditions

Interventions

PROCEDURE

3D printing

Manufacturing and use of a model printed in 3D

Sponsors & Collaborators

  • Hôpital Privé Les Franciscaines

    collaborator OTHER
  • Henri Mondor University Hospital

    collaborator OTHER
  • Rangueil Hospital

    collaborator OTHER
  • Clinique Pasteur Toulouse

    collaborator OTHER
  • University Hospital, Bordeaux

    collaborator OTHER
  • Clinique du Millenaire

    collaborator OTHER
  • Clinique Saint Pierre - Perpignan

    collaborator UNKNOWN
  • Hôpital Dupuytren

    collaborator OTHER
  • Hospital St. Joseph, Marseille, France

    collaborator OTHER
  • European Georges Pompidou Hospital

    collaborator OTHER
  • University Hospital, Grenoble

    collaborator OTHER
  • University Hospital, Lille

    collaborator OTHER
  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Vlad CIOBOTARU · Hôpital Privé Les Franciscaines

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2019-12-01
Completion
2019-12-01

Countries

  • France

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03330210 on ClinicalTrials.gov